- Home
- SHIP vs IPHA Comparison
SHIP vs IPHA Comparison
Compare SHIP & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHIP
- IPHA
- Stock Information
- Founded
- SHIP 2008
- IPHA 1999
- Country
- SHIP Greece
- IPHA France
- Employees
- SHIP N/A
- IPHA N/A
- Industry
- SHIP Marine Transportation
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- SHIP Consumer Discretionary
- IPHA Health Care
- Exchange
- SHIP Nasdaq
- IPHA Nasdaq
- Market Cap
- SHIP 141.8M
- IPHA 160.1M
- IPO Year
- SHIP 2007
- IPHA 2019
- Fundamental
- Price
- SHIP $7.04
- IPHA $1.93
- Analyst Decision
- SHIP Strong Buy
- IPHA Strong Buy
- Analyst Count
- SHIP 2
- IPHA 1
- Target Price
- SHIP $12.00
- IPHA $11.50
- AVG Volume (30 Days)
- SHIP 219.9K
- IPHA 21.5K
- Earning Date
- SHIP 03-06-2025
- IPHA 03-27-2025
- Dividend Yield
- SHIP 10.79%
- IPHA N/A
- EPS Growth
- SHIP 1660.03
- IPHA N/A
- EPS
- SHIP 2.11
- IPHA N/A
- Revenue
- SHIP $167,459,000.00
- IPHA $36,202,722.00
- Revenue This Year
- SHIP N/A
- IPHA N/A
- Revenue Next Year
- SHIP $10.86
- IPHA $93.37
- P/E Ratio
- SHIP $3.35
- IPHA N/A
- Revenue Growth
- SHIP 51.91
- IPHA N/A
- 52 Week Low
- SHIP $6.55
- IPHA $1.29
- 52 Week High
- SHIP $13.19
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- SHIP 47.49
- IPHA 45.85
- Support Level
- SHIP $7.00
- IPHA $1.91
- Resistance Level
- SHIP $7.53
- IPHA $2.05
- Average True Range (ATR)
- SHIP 0.26
- IPHA 0.06
- MACD
- SHIP -0.01
- IPHA -0.02
- Stochastic Oscillator
- SHIP 24.18
- IPHA 18.70
About SHIP Seanergy Maritime Holdings Corp.
Seanergy Maritime Holdings Corp is an international shipping company that provides marine dry bulk transportation services through the ownership and operation of dry bulk vessels. It generates a majority of its revenue from the vessels. The company fleet of vessels includes Fellowship, Championship, Partnership, Knightship, Lordship, Gloriuship, Leadership, Geniuship, Premiership, and Squireship among others.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.